Deborah L White

Summary

Affiliation: South Australia
Country: Australia

Publications

  1. ncbi request reprint OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
    Deborah L White
    Division of Hematology, Institute of Medical and Veterinary Science IMVS and Hanson Institute, Adelaide, South Australia
    Blood 108:697-704. 2006
  2. doi request reprint Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications
    Devendra K Hiwase
    Division of Haematology, Institute of Medical and Veterinary Science, University of Adelaide, Adelaide, South Australia, Australia
    Clin Cancer Res 14:3881-8. 2008
  3. doi request reprint Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib
    Deborah L White
    Haematology Department, Centre for Cancer Biology, SA Pathology IMVS Campus, University of Adelaide, Frome Road, Adelaide, Australia
    J Clin Oncol 28:2761-7. 2010
  4. ncbi request reprint In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
    Deborah White
    Division of Haematology, Institute of Medical and Veterinary Science IMVS and Hanson Institute, Adelaide, Australia
    Blood 106:2520-6. 2005
  5. doi request reprint Predicting the response of CML patients to tyrosine kinase inhibitor therapy
    Deborah L White
    Division of Haematology, SA Pathology IMVS RAH Campus, Frome Road, Adelaide, South Australia, Australia
    Curr Hematol Malig Rep 4:59-65. 2009
  6. ncbi request reprint Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia
    Deborah White
    Division of Hematology, Institute of Medical and Veterinary Science, Adelaide, Australia
    J Clin Oncol 25:4445-51. 2007
  7. ncbi request reprint Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
    Deborah L White
    Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 110:4064-72. 2007
  8. doi request reprint Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways
    Carine Tang
    Department of Haematology, SA Pathology, Adelaide, Australia
    Leuk Lymphoma 52:2139-47. 2011
  9. doi request reprint Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
    Laura N Eadie
    Division of Hematology, SA Pathology, Adelaide, South Australia, Australia
    Leuk Lymphoma 54:569-78. 2013
  10. pmc Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
    Deborah L White
    Department of Haematology, SA Pathology, RAH Campus, Adelaide, Australia
    Haematologica 97:907-14. 2012

Collaborators

Detail Information

Publications18

  1. ncbi request reprint OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
    Deborah L White
    Division of Hematology, Institute of Medical and Veterinary Science IMVS and Hanson Institute, Adelaide, South Australia
    Blood 108:697-704. 2006
    ..Determining interpatient and interdrug differences in cellular uptake and retention could allow individual optimization of kinase inhibitor therapy...
  2. doi request reprint Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications
    Devendra K Hiwase
    Division of Haematology, Institute of Medical and Veterinary Science, University of Adelaide, Adelaide, South Australia, Australia
    Clin Cancer Res 14:3881-8. 2008
    ..The relevance of OCT-1 activity and efflux pumps in determining intracellular uptake and retention (IUR) of dasatinib was assessed...
  3. doi request reprint Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib
    Deborah L White
    Haematology Department, Centre for Cancer Biology, SA Pathology IMVS Campus, University of Adelaide, Frome Road, Adelaide, Australia
    J Clin Oncol 28:2761-7. 2010
    ..We now report the impact of OA on loss of response, disease transformation, and survival after 5 years of imatinib...
  4. ncbi request reprint In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
    Deborah White
    Division of Haematology, Institute of Medical and Veterinary Science IMVS and Hanson Institute, Adelaide, Australia
    Blood 106:2520-6. 2005
    ..The IC50imatinib potentially provides a new prognostic indicator for molecular response in patients treated with imatinib...
  5. doi request reprint Predicting the response of CML patients to tyrosine kinase inhibitor therapy
    Deborah L White
    Division of Haematology, SA Pathology IMVS RAH Campus, Frome Road, Adelaide, South Australia, Australia
    Curr Hematol Malig Rep 4:59-65. 2009
    ..In the future, assays that directly assess the efficacy of the protein-drug interaction, taking into account factors intrinsic to the patient and the amount of drug freely available in the plasma, are likely to be of greater value...
  6. ncbi request reprint Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia
    Deborah White
    Division of Hematology, Institute of Medical and Veterinary Science, Adelaide, Australia
    J Clin Oncol 25:4445-51. 2007
    ..This suggests that patient-tailored dosing may be more rational than a fixed dose for all. Dose optimization potentially could be based on accurate measurement of the level of BCR-ABL kinase inhibition achieved in vivo...
  7. ncbi request reprint Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
    Deborah L White
    Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 110:4064-72. 2007
    ..This pretherapy assay identifies patients at greatest risk of suboptimal response where dose intensity is critical, and those likely to respond equally well to standard dose imatinib...
  8. doi request reprint Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways
    Carine Tang
    Department of Haematology, SA Pathology, Adelaide, Australia
    Leuk Lymphoma 52:2139-47. 2011
    ..This suggests that currently available TKIs share the same susceptibilities to drug resistance...
  9. doi request reprint Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
    Laura N Eadie
    Division of Hematology, SA Pathology, Adelaide, South Australia, Australia
    Leuk Lymphoma 54:569-78. 2013
    ..Imatinib and nilotinib appear to be transported by ABCB1 but do not interact strongly with ABCG2. Furthermore, ABCB1 efflux of nilotinib may be concentration-dependent with transport occurring at clinically relevant concentrations...
  10. pmc Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
    Deborah L White
    Department of Haematology, SA Pathology, RAH Campus, Adelaide, Australia
    Haematologica 97:907-14. 2012
    ....
  11. doi request reprint The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells
    Jane R Engler
    Division of Haematology, SA Pathology RAH Campus, Adelaide, Australia
    Blood 116:2776-8. 2010
    ..Therefore kinase inhibition in these mature cells, and not the CD34(+) cells, may be the key determinant of response in CML...
  12. doi request reprint Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
    Timothy P Hughes
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 112:3965-73. 2008
    ..Superior responses achieved in patients able to tolerate imatinib at 600 mg suggests that early dose intensity may be critical to optimize response in CP-CML. The trial was registered at www.ANZCTR.org.au as #ACTRN12607000614493...
  13. doi request reprint Predicting the response of CML patients to tyrosine kinase inhibitor therapy
    Deborah L White
    Haematology Department, SA Pathology RAH Site, Frome Road, Adelaide, South Australia
    Curr Hematol Malig Rep 6:88-95. 2011
    ....
  14. doi request reprint Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients
    Devendra K Hiwase
    Hematology Division, SA Pathology, Adelaide, SA 5000, Australia
    Expert Rev Hematol 4:285-99. 2011
    ..In addition, we provide commentary on the therapeutic options for patients who fail imatinib therapy...
  15. ncbi request reprint Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
    Deborah L White
    Division of Haematology, IMVS and Hanson Institute, Adelaide, Australia
    Leuk Lymphoma 49:1022-3. 2008
  16. pmc OCT-1 function varies with cell lineage but is not influenced by BCR-ABL
    Jane R Engler
    Department of Haematology, SA Pathology RAH Campus, Frome Road, Adelaide Australia
    Haematologica 96:213-20. 2011
    ..The present study examined whether cell lineage and BCR-ABL expression influenced OCT-1 activity...
  17. doi request reprint Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
    David M Ross
    Haematology, SA Pathology, Adelaide, Australia
    Blood 122:515-22. 2013
    ..These results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse. ..
  18. ncbi request reprint Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs
    Deborah L White
    Blood 109:3609-10. 2007